Angiochem

tsa hdac inhibitor |Peptide-Antibody Conjugates that Cross the Blood Brain Barrier

Angiochem was founded in 2003, is headquartered in Westmount, Canada, and has $55.5M in recorded funding across 3 rounds.

Headquarters
Westmount
Founded
2003
Business Model
B2B
Total Funding
$55.5M
Last Round
$42.0M Series BSep 2024
Rounds
3

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 3 funding rounds and 1 investor for this company. The full record is or through the API.

About

Angiochem discovers and develops peptide drug conjugates that use the LRP-1 mediated pathway to cross the blood-brain barrier and treat neurological diseases. Its development pipeline includes small molecules and biologics for potential treatment of primary brain cancer, brain metastases, lysosomal storage diseases and pain.

Summary

Angiochem is a Biotech company based in Westmount, Canada, founded in 2003. It has raised $55.5M in total across 3 rounds, most recently a $42.0M Series B round in Sep 2024. Investors include BDC Venture Capital.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BSep 2024
$42.0M

Sign up to see all 3 events

Funding: Seed through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Eikon TherapeuticsIPO

Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...

Hayward, United States201–500Artificial Intelligence, Biotech
Series DTotal funding$1.1BFeb 2025
Xaira Therapeutics

Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intellig...

South San Francisco, United States51–200Artificial Intelligence, Biotech
Series ATotal funding$1.0BApr 2024
OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech, Healthcare
Private EquityTotal funding$647.0MFeb 2026
Neumora TherapeuticsIPO

Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...

Watertown, United States51–200Biotech, Drug Discovery
Series BTotal funding$612.0MOct 2022

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Angiochem on Indexed.vc
<a href="https://indexed.vc/companies/angiochem"><img src="https://indexed.vc/api/badge/company/angiochem" alt="Angiochem on Indexed.vc" width="260" height="76" /></a>